Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 10, 2017 - Issue 1
Submit an article Journal homepage
1,097
Views
15
CrossRef citations to date
0
Altmetric
Drug Profile

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer

Kenzo SoejimaClinical and Translational Research Center, Keio University Hospital, Tokyo, JapanCorrespondence[email protected]
View further author information
,
Hiroyuki YasudaDivision of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, JapanView further author information
&
Toshiyuki HiranoDivision of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, JapanView further author information
Pages 31-38 | Received 27 Mar 2016, Accepted 23 Nov 2016, Published online: 02 Dec 2016

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Wolfgang Hohenforst-Schmidt, Paul Zarogoulidis, Michael Steinheimer, Naim Benhassen, Chrysanthi Sardeli, Nikos Stalikas, Melpomeni Toitou & Haidong Huang. (2017) Second-line afatinib administration in an elderly patient with squamous cell carcinoma. Therapeutics and Clinical Risk Management 13, pages 341-343.
Read now

Articles from other publishers (14)

Carmelo Laface, Felicia Maria Maselli, Anna Natalizia Santoro, Maria Laura Iaia, Francesca Ambrogio, Marigia Laterza, Chiara Guarini, Pierluigi De Santis, Martina Perrone & Palma Fedele. (2023) The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies. Pharmaceutics 15:6, pages 1604.
Crossref
Ziad Zalaquett, Maria Catherine Rita Hachem, Yara Kassis, Samir Hachem, Roland Eid, Hampig Raphael Kourie & David Planchard. (2023) Acquired resistance mechanisms to osimertinib: The constant battle. Cancer Treatment Reviews 116, pages 102557.
Crossref
Manjusha Dixit, Vinay J & Soham Choudhury. 2023. Gallbladder Cancer. Gallbladder Cancer 291 316 .
Reheman Yiming, Yasuto Takeuchi, Tatsunori Nishimura, Mengjiao Li, Yuming Wang, Makiko Meguro‐Horike, Takashi Kohno, Shin‐ichi Horike, Asuka Nakata & Noriko Gotoh. (2021) MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma. Cancer Science 112:9, pages 3810-3821.
Crossref
Leonard Clinton D'SouzaShruti MishraAnirban ChakrabortyAnusmita ShekherAnurag SharmaSubash Chandra Gupta. (2020) Oxidative Stress and Cancer Development: Are Noncoding RNAs the Missing Links?. Antioxidants & Redox Signaling 33:17, pages 1209-1229.
Crossref
Tommaso Bizzarro, Livia Bernardi, Raffaella Buda & Giulio Rossi. (2020) Cytological diagnosis of a rare synchronous non‐small cell lung cancer metastatic to the thyroid gland. Cytopathology 31:4, pages 329-332.
Crossref
Z.-X. Li, W. Zhao, Q. Sun, M.-S. Tang, Q.-J. Xia & M.-S. Dong. (2019) Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis. Clinical and Translational Oncology 22:6, pages 892-899.
Crossref
Yuan Tang, Nanying Che, Yang Yu, Yun Gao, Huaiyin Shi, Qin Feng, Bing Wei, Liheng Ma, Min Gao, Jie Ma & Dongmei Lin. (2019) Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs. Journal of Cancer Research and Clinical Oncology 146:2, pages 407-416.
Crossref
Mengya Tong, Mingzhao Gao, Yongping Xu, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Haitian Quan & Liguang Lou. (2019) SHR ‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD 9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met . Cancer Science 110:11, pages 3584-3594.
Crossref
Zhirui Zhang, Mengxiao Zhang, Hao Liu & Wu Yin. (2018) AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells. Journal of Cellular Biochemistry 120:1, pages 756-767.
Crossref
Tatsuya Nagano, Motoko Tachihara & Yoshihiro Nishimura. (2018) Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells 7:11, pages 212.
Crossref
Toshimitsu Yamaoka, Sojiro Kusumoto, Koichi Ando, Motoi Ohba & Tohru Ohmori. (2018) Receptor Tyrosine Kinase-Targeted Cancer Therapy. International Journal of Molecular Sciences 19:11, pages 3491.
Crossref
Hiroaki Akamatsu, Nobuyuki Katakami, Isamu Okamoto, Terufumi Kato, Young Hak Kim, Fumio Imamura, Masaharu Shinkai, Rachel A. Hodge, Hirohiko Uchida & Toyoaki Hida. (2018) Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA 3 trial . Cancer Science 109:6, pages 1930-1938.
Crossref
Martin Svatoň, Kristýna Hrdá & Miloš Pešek. (2017) Osimertinib - a new treatment option for patients with EGFR mutation T790M. Onkologie 11:2, pages 72-77.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.